News

The company also announced the appointments of two new directors, Marian Gorecki and Steven Rubin, and the departures of current board chairman and director Eugene Bauer and current

The new facility will be in the Sorrento Valley and will house the company’s research, preclinical and clinical development, pharmaceutical sciences and administrative operations. Barry Quart, president and

The investment was led by the TPG Biotechnology II fund with participation from existing investors, including MedVenture Associates, Thomas Fogarty and Emergent Ventures, and Lava Ventures. Sleep Solutions

The company will negotiate for the manufacture, testing and packaging of a revised line of health promotion supplements with a tie-in to some of the company’s other interests.

The patent covers Symplex, Symphogen’s proprietary process for discovering antibodies with diversity and specificity customized to a particular therapeutic application. The granted European patent is effective in 33

In the placebo-controlled ICARE study, more than 3,000 patients were tested for Haptoglobin phenotype, and the 801 patients who had the Hp2-2 phenotype and were also taking statins

Alta Partners and Healthcare Ventures led the round as part of an investor syndicate that included New Enterprise Associates and Polaris Venture Partners. The company will use the

These generic gemcitabine injections are therapeutic equivalents of Eli Lilly’s Gemzar injections available in two strengths: 200mg and 1g single use vial. Gemcitabine is an anticancer agent, used

Power3 Medical has determined the blood serum concentrations of these forty-seven biomarkers in samples from more than 750 neurodegenerative disease patients and normal control subjects. The results have